<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05077969</url>
  </required_header>
  <id_info>
    <org_study_id>LDOS-21-001-02</org_study_id>
    <nct_id>NCT05077969</nct_id>
  </id_info>
  <brief_title>Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2)</brief_title>
  <official_title>A Virtual Phase 2 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of the Combination of Famotidine and Celecoxib as a Post-exposure Prophylaxis (PEP) for Newly-infected COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leidos Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Leidos Life Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to test the efficacy and safety of combinations of two well-understood&#xD;
      agents - famotidine and celecoxib. Each of these agents separately demonstrate clinical&#xD;
      activity in mitigating COVID-19 disease symptoms or severity, and each of which appear to&#xD;
      have separate and complementary mechanisms of action.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Qualifying patients will have been confirmed positive for COVID-19 and have symptoms of World&#xD;
      Health Organization (WHO) Ordinal Scale for Clinical Improvement with scores of ≤3 on the&#xD;
      11-point scale and will be randomly assigned, in a 1:1 ratio, to one of two regimens, with&#xD;
      659 participants per group, as follows:&#xD;
&#xD;
      Group 1 (study product) participants will receive 80 mg famotidine (PO) QID + 400 mg&#xD;
      celecoxib as a first dose, followed by 200 mg celecoxib (PO) BID, for 5 days. Following this&#xD;
      5-day period, participants will continue their famotidine treatment for an additional 9 days.&#xD;
&#xD;
      Group 2 (reference therapy) participants will receive matching placebos QID and BID, for 5&#xD;
      days. Following this 5-day period, participants will continue to receive matching famotidine&#xD;
      placebo, QID, for an additional 9 days.&#xD;
&#xD;
      Safety and efficacy of famotidine and celecoxib will be evaluated.&#xD;
&#xD;
      This is a completely virtual trial and you can participate from your own home. Please call&#xD;
      1-888-370-9330 to speak to someone regarding study participation in your area.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants randomized 1:1, study drug:placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with at least one COVID-19-related medically attended contact due to increased COVID-19 symptom severity</measure>
    <time_frame>Through Day 30</time_frame>
    <description>Medically attended contact will be measured in whole numbers and reported as &quot;1 medically attended contact&quot; each time, in the electronic data capture system for all study participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with at least one COVID-19-related medically attended contact due to death (all-cause mortality).</measure>
    <time_frame>Through Day 30</time_frame>
    <description>Medically attended contact will be measured in whole numbers and reported as &quot;1 medically attended contact&quot; in the electronic data capture system for all study participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Serious Adverse Events (SAE)as assessed by participant withdrawal</measure>
    <time_frame>90 days</time_frame>
    <description>Study discontinuation will be measured in whole units, by number of participants who are removed with the reason of &quot;SAE&quot; and captured by the electronic data capture system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of death</measure>
    <time_frame>90 days</time_frame>
    <description>Deaths will be captured by whole numbers, by number of participants who are removed from the study with reason as &quot;death&quot; in the electronic data capture system.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1465</enrollment>
  <condition>2019 Novel Coronavirus Disease</condition>
  <condition>2019 Novel Coronavirus Infection</condition>
  <condition>2019-nCoV Disease</condition>
  <condition>2019-nCoV Infection</condition>
  <condition>COVID-19</condition>
  <condition>COVID-19 Pandemic</condition>
  <condition>COVID-19 Virus Disease</condition>
  <condition>COVID-19 Virus Infection</condition>
  <condition>Covid19</condition>
  <condition>Coronavirus Disease 2019</condition>
  <condition>SARS-CoV2 Infection</condition>
  <condition>SARS-CoV-2 Acute Respiratory Disease</condition>
  <arm_group>
    <arm_group_label>Group 1 (Study Product)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, participants will continue their famotidine treatment for an additional 9 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (Reference Therapy)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebos QID and BID, for 5 days. Following this 5-day period, participants will continue to receive matching famotidine placebo, QID, for an additional 9 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine</intervention_name>
    <description>80 mg tablet, QID for 14 days</description>
    <arm_group_label>Group 1 (Study Product)</arm_group_label>
    <other_name>Pepcid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>400 mg (initial dose), then 200 mg capsule, BID for 5 days</description>
    <arm_group_label>Group 1 (Study Product)</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet, QID for 14 days; capsule, BID for 5 days</description>
    <arm_group_label>Group 2 (Reference Therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participants must be at least 18 years of age, inclusive, at the time&#xD;
             of signing the informed consent form.&#xD;
&#xD;
          -  Confirmed SARS-CoV-2 polymerase chain reaction (PCR) positive patient within 5 days of&#xD;
             enrollment, as shown by medical history and reported PCR test result.&#xD;
&#xD;
          -  Reports having one or more symptoms consistent with SARS-CoV-2, as defined in Master&#xD;
             Protocol Appendix 3 Table 4.&#xD;
&#xD;
          -  COVID-19 diagnosis must be WHO grade ≤3.&#xD;
&#xD;
          -  Contraceptive use by men or women should be consistent with Appendix 4 of the Master&#xD;
             protocol (LDOS-21-001).&#xD;
&#xD;
          -  Reliable access to the Internet via a browser installed on personal device or&#xD;
             computer.&#xD;
&#xD;
          -  Capable of understanding and providing signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Ongoing antiviral or antiretroviral treatment&#xD;
&#xD;
          -  Known history of HIV&#xD;
&#xD;
          -  Ongoing anti-inflammatory treatment that cannot be temporarily discontinued during the&#xD;
             study. This includes nonsteroidal anti-inflammatory drugs (NSAIDs), and&#xD;
             corticosteroids - including Dexamethasone (dexamethasone administration restricted to&#xD;
             recommended standard of care use per NIH COVID-19 Guidelines)&#xD;
&#xD;
               1. drugs dependent on gastric pH for absorption, e.g., dasatinib, delavirdine,&#xD;
                  mesylate, cefditoren, and fosamprenavir;&#xD;
&#xD;
               2. tizanidine (CYP1A2) substrate;&#xD;
&#xD;
               3. drugs that interfere with hemostasis (e.g., warfarin, aspirin, selective&#xD;
                  serotonin reuptake inhibitors [SSRIs]/serotonin norepinephrine reuptake&#xD;
                  inhibitors (SNRIs]);&#xD;
&#xD;
               4. angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers&#xD;
                  (ARB), or beta-blockers;&#xD;
&#xD;
               5. diuretics;&#xD;
&#xD;
               6. digoxin&#xD;
&#xD;
          -  Ongoing treatment that cannot be temporarily discontinued during the study, with:&#xD;
             antimalarials, antiarrhythmics, tricyclic antidepressants, natalizumab, quinolones,&#xD;
             macrolides, agalsidase alfa and beta&#xD;
&#xD;
          -  Ongoing famotidine or celecoxib or other COVID-19 clinical investigational&#xD;
             treatment(s) within the past 30 days, or current participation in another&#xD;
             investigational clinical trial&#xD;
&#xD;
          -  History of asthma, urticaria, or other allergic-type reactions after taking aspirin or&#xD;
             other NSAIDs&#xD;
&#xD;
          -  History of immunosuppression&#xD;
&#xD;
          -  Rejection of participation by Principal Investigator or Sponsor&#xD;
&#xD;
          -  Any contraindication for famotidine or celecoxib treatment:&#xD;
&#xD;
               1. Famotidine or celecoxib hypersensitivity&#xD;
&#xD;
               2. Retinopathy, visual field or visual acuity disturbances&#xD;
&#xD;
               3. History of cardiovascular disease, such as congestive heart failure, QT&#xD;
                  prolongation, myocardial infarction, bradycardia (&lt;50 bpm), ventricular&#xD;
                  tachycardia, other arrhythmias&#xD;
&#xD;
               4. Myasthenia gravis&#xD;
&#xD;
               5. Psoriasis or porphyria&#xD;
&#xD;
               6. History of renal failure/dialysis or a glomerular clearance &lt;60 mL/min&#xD;
&#xD;
               7. History of severe hypoglycemia&#xD;
&#xD;
               8. Moderate or severe hepatic impairment, e.g., Child-Pugh Class B or C&#xD;
&#xD;
               9. Known or suspected to be poor CYP2C9 metabolizers based on genotype or previous&#xD;
                  history or experience with other CYP2C9 substrates, such as warfarin and&#xD;
                  phenytoin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian A Roberts, MS, PMP</last_name>
    <role>Study Director</role>
    <affiliation>Leidos, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>www.treatmycovid.com</last_name>
    <phone>866-893-5666</phone>
    <email>brian.a.roberts@leidos.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brian A Roberts, MS, PMP</last_name>
    <phone>240-529-0455</phone>
    <email>brian.a.roberts@leidos.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Integrated Therapeutic Solutions USA, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dimitri Fitsialos, Sr. Director</last_name>
      <phone>888-370-9330</phone>
      <email>dfitsialos@integratedtsi.com</email>
    </contact>
    <contact_backup>
      <last_name>Gretchen Pessagno, Director</last_name>
      <phone>1-888-370-9330</phone>
      <email>gpessagno@integratedtsi.com</email>
    </contact_backup>
    <investigator>
      <last_name>Salman Naqvi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrated Therapeutic Solutions USA, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dimitri Fitsialos, Sr. Director</last_name>
      <phone>888-370-9330</phone>
      <email>dfitsialos@integratedtsi.com</email>
    </contact>
    <contact_backup>
      <last_name>Gretchen Pessagno, Director</last_name>
      <phone>1-888-370-9330</phone>
      <email>gpessagno@integratedtsi.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sheba Asghar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrated Therapeutic Solutions USA, Inc.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dimitri Fitsialos, Sr. Director</last_name>
      <phone>888-370-9330</phone>
      <email>dfitsialos@integratedtsi.com</email>
    </contact>
    <contact_backup>
      <last_name>Gretchen Pessagno, Director</last_name>
      <phone>1-888-370-9330</phone>
      <email>gpessagno@integratedtsi.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nadya Mehdi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrated Therapeutic Solutions USA, Inc</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20878</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dimitri Fitsialos, Sr. Director</last_name>
      <phone>888-370-9330</phone>
      <email>dfitsialos@integratedtsi.com</email>
    </contact>
    <contact_backup>
      <last_name>Gretchen Pessagno, Director</last_name>
      <phone>1.888.370.9330</phone>
      <email>gpessagno@integratedtsi.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sheba Asghar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrated Therapeutic Solutions USA, Inc.</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dimitri Fitsialos, Sr. Director</last_name>
      <phone>888-370-9330</phone>
      <email>dfitsialos@integratedtsi.com</email>
    </contact>
    <contact_backup>
      <last_name>Gretchen Pessagno, Director</last_name>
      <phone>1-888-370-9330</phone>
      <email>gpessagno@integratedtsi.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rubina Raza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrated Therapeutic Solutions USA, Inc.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10005</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dimitri Fitsialos, Sr. Director</last_name>
      <phone>888-370-9330</phone>
      <email>dfitsialos@integratedtsi.com</email>
    </contact>
    <contact_backup>
      <last_name>Gretchen Pessagno, Director</last_name>
      <phone>1-888-370-9330</phone>
      <email>gpessagno@integratedtsi.com</email>
    </contact_backup>
    <investigator>
      <last_name>Huma Naqvi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrated Therapeutic Solutions USA, Inc.</name>
      <address>
        <city>Marion</city>
        <state>North Carolina</state>
        <zip>28752</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dimitri Fitsialos, Sr. Director</last_name>
      <phone>888-370-9330</phone>
      <email>dfitsialos@integratedtsi.com</email>
    </contact>
    <contact_backup>
      <last_name>Gretchen Pessagno, Director</last_name>
      <phone>1-888-370-9330</phone>
      <email>gpessagno@integratedtsi.com</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Stripling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrated Therapeutic Solutions USA, Inc.</name>
      <address>
        <city>Huntingdon</city>
        <state>Pennsylvania</state>
        <zip>16652</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dimitri Fitsialos, Sr. Director</last_name>
      <phone>888-370-9330</phone>
      <email>dfitsialos@integratedtsi.com</email>
    </contact>
    <contact_backup>
      <last_name>Gretchen Pessagno, Director</last_name>
      <phone>1-888-370-9330</phone>
      <email>gpessagno@integratedtsi.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sheba Asghar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrated Therapeutic Solutions USA, Inc.</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29492</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dimitri Fitsialos, Sr. Director</last_name>
      <phone>888-370-9330</phone>
      <email>dfitsialos@integratedtsi.com</email>
    </contact>
    <contact_backup>
      <last_name>Gretchen Pessagno, Director</last_name>
      <phone>1-888-370-9330</phone>
      <email>gpessagno@integratedtsi.com</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Stripling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrated Therapeutic Solutions USA, Inc.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75219</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dimitri Fitsialos, Sr. Director</last_name>
      <phone>888-370-9330</phone>
      <email>dfitsialos@integratedtsi.com</email>
    </contact>
    <contact_backup>
      <last_name>Gretchen Pessagno, Director</last_name>
      <phone>1-888-370-9330</phone>
      <email>gpessagno@integratedtsi.com</email>
    </contact_backup>
    <investigator>
      <last_name>Salman Ahmed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.treatmycovid.com</url>
    <description>Website to learn more about this virtual COVID-19 study</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>COVID</keyword>
  <keyword>COVID19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>It is not yet known if there will be a plan to make individual participant data (IPD) available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

